Wealthfront Advisers LLC Makes New $19.24 Million Investment in Danaher Corporation $DHR

Wealthfront Advisers LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 26,725 shares of the conglomerate’s stock, valued at approximately $19,243,000.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Danaher in the 2nd quarter worth about $10,492,520,000. State Street Corp boosted its position in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after buying an additional 472,608 shares during the period. Capital International Investors grew its stake in Danaher by 8.9% in the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after acquiring an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after acquiring an additional 1,334,221 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after acquiring an additional 1,517,904 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on DHR shares. DZ Bank initiated coverage on Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Argus decreased their target price on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, Wells Fargo & Company dropped their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Price Performance

Shares of DHR opened at $199.62 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a 50 day moving average price of $193.74 and a 200-day moving average price of $192.50. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market capitalization of $140.33 billion, a PE ratio of 35.46, a PEG ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company posted $0.77 earnings per share. Equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.